Randomised, triple-blind, placebo-controlled parallel trial (n=37) of IV ketamine infusions (6 infusions over 3 weeks, twice weekly) versus saline in treatment-resistant major depressive disorder.
Randomised, triple-blind, parallel-group trial testing repeated intravenous ketamine as augmentation for treatment-resistant major depressive disorder; participants received six infusions over three weeks (twice weekly).
Prior single-dose ketamine studies showed acute reductions in depression scores and suicidal ideation; this study evaluated feasibility and efficacy of repeated administration versus saline on depressive symptoms.
Intravenous ketamine infusions given twice weekly for 3 weeks (6 total) as augmentation of ongoing antidepressant regimen.
IV infusions twice weekly for 3 weeks (6 total) as augmentation of ongoing antidepressant regimen.
Intravenous normal saline infusions matching ketamine schedule (6 infusions over 3 weeks).
Normal saline infusions matching ketamine schedule (6 total).